OasisLMS

Activity Description

Hypertrophic cardiomyopathy (HCM) may affect as many as 1 in 200 people, with a mortality rate about three times greater than in those without HCM. Historically, treatment for severe symptomatic obstructive HCM (oHCM) was limited to invasive treatments such as septal reduction therapy (SRT) or medications that inconsistently addressed symptoms. In 2022, a first-in-class cardiac myosin inhibitor (CMI) was approved for oHCM. CMIs target the underlying pathophysiology of HCM, alleviate symptoms, improve functional outcomes, and are potentially disease-modifying (a characteristic relevant beyond oHCM). Notably, phase 3 evidence has shown that CMIs can significantly reduce the need for SRT in severe cases of oHCM. How is this innovative class impacting patient care strategies and clinical workflows?

During a recent Clinical Consults live virtual symposium, PeerView, Mended Hearts, and expert panelists explored clinical research and real-world evidence for CMIs through the lens of everyday patient care. Join us for this on-demand activity to improve your skills in identifying appropriate patients for CMI therapy and crafting individualized management plans using the principles of shared decision-making. By the end, you will also be able to better explain the how and why of CMIs and understand their potential in nHCM and HFpEF. If you couldn’t join us for the live event, watch now to start remodeling your clinical practice!

Please claim your continuing education credits on the Peerview site!

You can access the on-demand course here!